Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Sponsor
Chinese PLA General Hospital
Study ID
NCT02930265
Status
Unknown

Conditions

  • Ischemic Cardiomyopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)

Study Details

It has been known that liraglutide reduces infarct size, improved left ventricular function, reduce myocardial stunning, and play a protective role in myocardial ischemia-reperfusion injury for patients with acute myocardial infarction. But it is not sure whether liraglutide can benefit patients with ischemic cardiomyopathy. This study aim to explore the effect of Liraglutide in improving cardiac function for patients with ischemic cardiomyopathy.

Key Dates

Start date
Sep 30, 2016
Status verified
Oct 2016
Primary completion
Feb 28, 2018
Completion
Mar 31, 2018

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Liraglutide intervention group
    Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
  • No Intervention: Control group
    Control group will accept ischemic cardiomyopathy conventional drugs and a placebo

Primary Outcome Measure

main adverse cardiovascular events [ Time Frame: Followed up for 6 months after enrolled in the study ]

Related Studies